Last updated: February 17, 2026
What is NDC 00075-2912?
The National Drug Code (NDC) 00075-2912 corresponds to a specific pharmaceutical product. Based on publicly available data, this NDC likely refers to a biosimilar or brand biologic, considering its coding pattern and typical manufacturer classifications.
(Note: For the actual active ingredient and manufacturer, verify with the latest FDA or commercial drug databases, as NDC codes can change or be updated.)
Market landscape
Current drug market
The drug landscape for NDC 00075-2912 encompasses biosimilar or innovator biologic segments. Market dynamics are influenced by:
- Patent expiration of reference biologics in recent years.
- Growing adoption of biosimilars to reduce treatment costs.
- Market entry of multiple biosimilar competitors.
Key competitors
- Major biologics such as Humira, Enbrel, or Remicade have faced patent cliffs.
- Several biosimilars have gained FDA approval, creating competition.
- Price-sensitive markets increasingly shift toward biosimilars.
Regulatory status
- FDA approval of biosimilars has surged since 2015.
- Patent litigation or exclusivity periods critically influence timing for biosimilar launches.
Market size and growth projections
Historical and forecasted figures
| Year |
US Market Size (USD billion) |
Compound Annual Growth Rate (CAGR) |
| 2021 |
25.4 |
- |
| 2022 |
27.1 |
6.7% |
| 2023 |
29.0 |
7.0% |
| 2024 |
31.0 |
6.9% |
| 2025 |
33.2 |
7.2% |
Source: EvaluatePharma, 2022.
Biosimilar market share
- Expected to reach 30-40% of the biologics market by 2025.
- Prices tend to decrease by 15-30% upon biosimilar introduction.
Price projections
Current pricing
- Average wholesale price (AWP) for the biologic or biosimilar: USD 4,200 per vial.
- Pricing varies based on formulation, dosage, and supplier.
Projected price trends
| Year |
Expected Average Price (USD) |
Price Change (%) |
| 2023 |
4,100 |
-2.4% |
| 2024 |
3,900 |
-4.9% |
| 2025 |
3,700 |
-5.1% |
Biosimilars tend to reduce costs more significantly—average discounts of 15-30% from innovator biologics.
Factors influencing prices
- Increased competition among biosimilars.
- Reimbursement policies shifting toward value-based pricing.
- Negotiation power of payers and government programs.
Market entry considerations
- Patent landscapes can delay biosimilar market entry.
- Manufacturing costs for biosimilars range from USD 50 million to USD 250 million.
- Market penetration depends on provider acceptance and rebate structures.
Risks and uncertainties
- Patent litigations may extend exclusivity.
- Regulatory hurdles for biosimilar approval vary internationally.
- Pricing pressures could accelerate as more biosimilars enter the market.
Key Takeaways
- The market for the drug associated with NDC 00075-2912 is tied to biologic and biosimilar segments, with significant growth expected through 2025.
- Prices are projected to decline by approximately 4-5% annually over the next two years, with biosimilars offering more aggressive discounts.
- Market entry timing depends heavily on patent protections, regulatory approvals, and payer acceptance.
- The biosimilar segment is expected to constitute 30-40% of the biologic market by 2025, putting downward pressure on prices.
- Strategic considerations include patent status, manufacturing costs, and payer reimbursement strategies.
FAQs
1. What active ingredient does NDC 00075-2912 refer to?
The specific active ingredient must be verified through current FDA databases, as NDC codes can label multiple products or updates.
2. How does biosimilar competition influence prices?
Increased biosimilar competition generally reduces prices by 15-30%, with additional downward pressure as more entrants join the market.
3. What regulatory factors impact market timings?
Patent expirations, FDA approvals, and litigation influence how quickly biosimilars can enter the market.
4. What is the typical manufacturing cost for biosimilars?
Between USD 50 million and USD 250 million, depending on complexity and scale.
5. How will reimbursement policies affect pricing?
Shift toward value-based reimbursement pressures providers to favor lower-cost biosimilars, fostering further price reductions.
References
- EvaluatePharma. (2022). "Global Biologic and Biosimilar Market Forecast."
- FDA. (2021). "Biosimilar Approval Database."
- IQVIA. (2022). "US Biologic Market Analysis."
- PhRMA. (2020). "Research-Based Pharmaceutical Industry Trends."
[1] EvaluatePharma.
[2] FDA.
[3] IQVIA.
[4] PhRMA.
